Your browser doesn't support javascript.
loading
Estimating individualized treatment effects from randomized controlled trials: a simulation study to compare risk-based approaches.
Rekkas, Alexandros; Rijnbeek, Peter R; Kent, David M; Steyerberg, Ewout W; van Klaveren, David.
Afiliação
  • Rekkas A; Department of Medical Informatics, Erasmus Medical Center, P.O. Box 2040, 3000, CA, Rotterdam, The Netherlands. a.rekkas@erasmusmc.nl.
  • Rijnbeek PR; Department of Medical Informatics, Erasmus Medical Center, P.O. Box 2040, 3000, CA, Rotterdam, The Netherlands.
  • Kent DM; Predictive Analytics and Comparative Effectiveness Center, Institute for Clinical Research and Health Policy Studies, Tufts Medical Center, Boston, MA, USA.
  • Steyerberg EW; Department of Biomedical Data Sciences, Leiden University Medical Center, Leiden, The Netherlands.
  • van Klaveren D; Department of Public Health, Erasmus Medical Center, Rotterdam, The Netherlands.
BMC Med Res Methodol ; 23(1): 74, 2023 03 28.
Article em En | MEDLINE | ID: mdl-36977990
ABSTRACT

BACKGROUND:

Baseline outcome risk can be an important determinant of absolute treatment benefit and has been used in guidelines for "personalizing" medical decisions. We compared easily applicable risk-based methods for optimal prediction of individualized treatment effects.

METHODS:

We simulated RCT data using diverse assumptions for the average treatment effect, a baseline prognostic index of risk, the shape of its interaction with treatment (none, linear, quadratic or non-monotonic), and the magnitude of treatment-related harms (none or constant independent of the prognostic index). We predicted absolute benefit using models with a constant relative treatment effect; stratification in quarters of the prognostic index; models including a linear interaction of treatment with the prognostic index; models including an interaction of treatment with a restricted cubic spline transformation of the prognostic index; an adaptive approach using Akaike's Information Criterion. We evaluated predictive performance using root mean squared error and measures of discrimination and calibration for benefit.

RESULTS:

The linear-interaction model displayed optimal or close-to-optimal performance across many simulation scenarios with moderate sample size (N = 4,250; ~ 785 events). The restricted cubic splines model was optimal for strong non-linear deviations from a constant treatment effect, particularly when sample size was larger (N = 17,000). The adaptive approach also required larger sample sizes. These findings were illustrated in the GUSTO-I trial.

CONCLUSIONS:

An interaction between baseline risk and treatment assignment should be considered to improve treatment effect predictions.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Ensaios Clínicos Controlados Aleatórios como Assunto Tipo de estudo: Clinical_trials / Etiology_studies / Guideline / Prognostic_studies / Risk_factors_studies Limite: Humans Idioma: En Ano de publicação: 2023 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Ensaios Clínicos Controlados Aleatórios como Assunto Tipo de estudo: Clinical_trials / Etiology_studies / Guideline / Prognostic_studies / Risk_factors_studies Limite: Humans Idioma: En Ano de publicação: 2023 Tipo de documento: Article